Abstract
This study verifies the existence of strategic groups among biotechnology firms that have filed for an initial public offering (IPO). We found three distinct groupings based on the dimensions of competitive scope and growth. Differences also exist between these groupings and an aspect of market influence – the ability to attract strategic partners. We found that biotechnology IPOs that seek greater breadth in competitive scope and growths also have more alliance partners. This paper adds to our knowledge of the bio-pharmaceutical market-sector and the strategic intentions of firms in an emerging, disruptive industry and their ability to attract strategic coalition partners.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
